Gliomatosis Cerebri Diagnosis and Treatment
Gliomatosis cerebri is a primary central nervous system (CNS) tumor. This means it begins in the brain or spinal cord. This tumor is no longer recognized as a formal diagnosis, rather gliomatosis cerebri refers to a special pattern of diffuse and extensive growth of glioma cells, invading multiple lobes of the brain. Gliomas of different grade and cell of origin (astrocytes, oligodendrocytes) can grow with this pattern, and very little is understood about the molecular basis of the disease. More research is needed to discover the origin of these tumors and to improve their treatment.
What are the grades of gliomatosis cerebri?
Primary CNS tumors are graded based on the tumor location, tumor type, extent of tumor spread, genetic findings, the patient’s age, and tumor remaining after surgery, if surgery is possible.
Gliomatosis cerebri are grouped in three grades based on their characteristics.
- Grade II gliomatosis cerebri are mid-grade tumors. This means the tumors have a higher chance of coming back after being removed. They usually have a change in the genes called isocitrate dehydrogenase (IDH).
- Grade III and IV gliomatosis cerebri are malignant (cancerous). This means they are fast-growing tumors that often become resistant to treatment.
What do gliomatosis cerebri look like on an MRI?
Gliomatosis cerebri usually appear abnormal in three or more lobes of the brain.
- Type 1 shows no obvious mass, but a widespread tumor pattern or a fluffy looking abnormality.
- Type 2 shows a widespread fluffy looking tumor pattern, but also a tumor mass.
Gliomatosis cerebri is diagnosed based on imaging, instead of pathology like most other tumor types.
What causes gliomatosis cerebri?
The cause of gliomatosis cerebri are not known.
Where does gliomatosis cerebri form?
Cancer is a genetic disease – that is, cancer is caused by certain changes to genes that control the way our cells function. Genes may be mutated (changed) in many types of cancer, which can increase the growth and spread of cancer cells. Gliomatosis cerebri commonly arises from glial cells in the brain. Glial cells support and insulate neurons and are the most abundant cells in the brain. When seen under a microscope the tumor cells resemble glial cells and involve many areas of the cerebrum. This is why this is named gliomatosis cerebri.
Do gliomatosis cerebri spread?
Gliomatosis cerebri can spread to other areas of the CNS through cerebrospinal fluid (CSF). They can spread quickly and deeply into surrounding brain tissue. They do not spread outside the CNS.
What are symptoms of gliomatosis cerebri?
Symptoms related to a gliomatosis cerebri depend on the tumor’s location and person’s age. Here are some possible symptoms that can occur.
Gliomatosis Cerebri Symptoms
- Mood changes
- Changes in thinking and memory
Who is diagnosed with gliomatosis cerebri?
Gliomatosis cerebri occur most often in people between the ages of 46 and 53, but can occur at any age. Gliomatosis cerebri occur slightly more often in males than females. An estimated 247 people are living with this tumor in the United States.
What is the prognosis of gliomatosis cerebri?
The likely outcome of the disease or chance of recovery is called prognosis.
Gliomatosis Cerebri Prognosis
The relative 5-year survival rate for gliomatosis cerebri is 18.8% but know that many factors can affect prognosis. This includes the tumor grade and type, traits of the cancer, the person’s age and health when diagnosed, and how they respond to treatment. If you want to understand your prognosis, talk to your doctor.
What are treatment options for gliomatosis cerebri?
The first treatment for a gliomatosis cerebri is surgery, if possible. The goal of surgery is to obtain tissue to determine the tumor type and remove as much of the tumor as possible without causing more symptoms for the person. Surgery is usually limited to a biopsy, as there is not a central mass for removal.
After surgery, there is no standard treatment for gliomatosis cerebris. Other treatments may include radiation, chemotherapy, or clinical trials. Treatments are decided by the patient’s healthcare team based on the patient’s age, remaining tumor after surgery, tumor type, and tumor location. This tumor type may respond well to radiation therapy, but patients should discuss the full risks and benefits with their healthcare team, as radiation to a large volume of brain tissue puts normal brain tissue at risk for problems. Chemotherapy is also a treatment that may be recommended during radiation, after radiation is completed, or if the tumor recurs after initial treatment. Temozolomide is a drug that is often used, as this is the therapy for astrocytic type tumors. Clinical trials, with new chemotherapy, targeted therapy, or immunotherapy drugs, may also be available and can be a possible treatment option.
Open Clinical Studies for Gliomatosis Cerebri
- Outcomes and Risk Project for Patients with Rare CNS Cancers
- Evaluation of the Natural History and Specimen Banking for Patients with CNS Cancers
- Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers
- Nivolumab for Patients with IDH-Mutant Gliomas
- Collaborating Globally to Impact Outcomes for Rare Brain and Spine Cancers
- Inspiring Messages from the Brain Tumor Community
- Advice from the Brain Tumor Community
- Living with a Brain or Spine Tumor
Find doctors and nurses with experience treating this tumor.